ha14-1 has been researched along with Malignant Melanoma in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lickliter, JD | 1 |
| Cox, J | 1 |
| McCarron, J | 1 |
| Martinez, NR | 1 |
| Schmidt, CW | 1 |
| Lin, H | 1 |
| Nieda, M | 1 |
| Nicol, AJ | 1 |
1 other study available for ha14-1 and Malignant Melanoma
| Article | Year |
|---|---|
Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
Topics: Adult; Antineoplastic Agents; Benzopyrans; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; | 2007 |